Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Costanzo, Antonio (Humanitas Clinical and Research Center IRCCS)
de Jong, Elke M. G. J. (Radboud University Medical Center)
Torres, Tiago (University of Porto)
Warren, Richard B. (The University of Manchester)
Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos))
Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya))
Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit))
Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia))
Jazra, Maria (Janssen-Cilag (París, França))
Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica))
Conrad, Curdin (University of Lausanne)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices. This post-hoc analysis of the 5-year VOYAGE 1 clinical trial compares baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for ≥ 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model. Guselkumab plasma trough concentrations in both response groups were assessed from Weeks 4-156. Of patients who started guselkumab treatment at Week 0 or at Week 16 after switching from placebo, 22. 7% (112/494) maintained PASI = 0 for ≥ 156 consecutive weeks. Numerical differences in baseline characteristics, including age, obesity, diabetes, PASI score, disease duration, smoking status, and psoriatic arthritis comorbidity, were identified between the PASI = 0 group and comparator group. Plasma guselkumab levels were consistently higher in the PASI = 0 group. Multiple logistic regression analysis revealed absence of diabetes, lower Dermatology Life Quality Index score at baseline, and higher Week 4 guselkumab plasma concentration as significantly (p < 0. 05) associated with the PASI = 0 group. A substantial (22. 7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of ≥ 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches. NCT02207231.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	American Journal of Clinical Dermatology, Vol. 25 (october 2023) , p. 315-325, ISSN 1179-1888

DOI: 10.1007/s40257-023-00816-1
PMID: 37804472

11 p, 1.8 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados